title: Engineered nanoparticles for drug delivery in cancer therapy.
abstract: In medicine, nanotechnology has sparked a rapidly growing interest as it promises to solve a number of issues associated with conventional therapeutic agents, including their poor water solubility (at least, for most anticancer drugs), lack of targeting capability, nonspecific distribution, systemic toxicity, and low therapeutic index. Over the past several decades, remarkable progress has been made in the development and application of engineered nanoparticles to treat cancer more effectively. For example, therapeutic agents have been integrated with nanoparticles engineered with optimal sizes, shapes, and surface properties to increase their solubility, prolong their circulation half-life, improve their biodistribution, and reduce their immunogenicity. Nanoparticles and their payloads have also been favorably delivered into tumors by taking advantage of the pathophysiological conditions, such as the enhanced permeability and retention effect, and the spatial variations in the pH value. Additionally, targeting ligands (e.g., small organic molecules, peptides, antibodies, and nucleic acids) have been added to the surface of nanoparticles to specifically target cancerous cells through selective binding to the receptors overexpressed on their surface. Furthermore, it has been demonstrated that multiple types of therapeutic drugs and/or diagnostic agents (e.g., contrast agents) could be delivered through the same carrier to enable combination therapy with a potential to overcome multidrug resistance, and real-time readout on the treatment efficacy. It is anticipated that precisely engineered nanoparticles will emerge as the next-generation platform for cancer therapy and many other biomedical applications.
authors.affiliation: The Wallace H. Coulter Department of Biomedical Engineering, Georgia Institute of Technology and Emory University, Atlanta, GA 30332 (USA).
authors.forename: Tianmeng
authors.initials: T
authors.lastname: Sun
authors.forename: Yu Shrike
authors.initials: YS
authors.lastname: Zhang
authors.forename: Bo
authors.initials: B
authors.lastname: Pang
authors.forename: Dong Choon
authors.initials: DC
authors.lastname: Hyun
authors.forename: Miaoxin
authors.initials: M
authors.lastname: Yang
authors.forename: Younan
authors.initials: Y
authors.lastname: Xia
mesh_terms: D000818:Animals; D000970:Antineoplastic Agents / Q000008:administration & dosage*; D003692:Delayed-Action Preparations / Q000737:chemistry* / Q000378:metabolism; D016503:Drug Delivery Systems; D006801:Humans; D050997:Nanomedicine / Q000379:methods; D053758:Nanoparticles / Q000737:chemistry* / Q000378:metabolism; D036103:Nanotechnology / Q000379:methods; D009369:Neoplasms / Q000188:drug therapy*
chemical_list: D000970:Antineoplastic Agents; D003692:Delayed-Action Preparations
keywords: cancer therapy; controlled release; drug delivery; nanomedicine; nanoparticles